Table 2.
Seroconversion in 83 patients with hematological malignancies.
| Disease | Patients |
|---|---|
| B-cell lymphoproliferative disorders | 36/48 |
| Chronic lymphocytic leukemia | 4/7 |
| Indolent non-Hodgkin lymphoma | 18/25 |
| Follicular lymphoma | 10/14 |
| Marginal zone lymphoma | 4/6 |
| MALT lymphoma | 0/1 |
| Lymphoplasmacytic lymphoma | 3/3 |
| Hairy-cell leukemia | 1/1 |
| Aggressive non-Hodgkin lymphoma | 14/16 |
| Diffuse large B-cell lymphoma | 9/10 |
| Cutaneous B-cell lymphoma | 2/3 |
| Burkitt lymphoma | 2/2 |
| Mediastinal B-cell lymphoma | 1/1 |
| Monoclonal gammopathies | 17/28 |
| MGUS | 1/1 |
| Smoldering multiple myeloma | 2/2 |
| Active multiple myeloma | 14/25 |
| Hodgkin lymphoma | 6/7 |
| Treatment | |
| Never received | 14/17 |
| On | 6/17 |
| Off | 39/49 |
| Lines of therapy | |
| 1 | 35/44 |
| 2 or more | 10/22 |
| Previous treatment | |
| Anti-CD20 | 22/27 |
| Anti-CD38 | 6/12 |
| Immunomodulatory drugs | 11/22 |
| Autologous stem cell transplantation | 14/20 |
| Depth of response before vaccination in treated patients | |
| Complete response | 54/66 |
| No complete response | 12/66 |